Agile Therapeutics, Inc. reaffirmed revenue guidance for the Full Year 2023. For the year, the company reaffirmed Net Revenue of At Least $25 Million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.313 USD | -1.26% | -7.94% | -83.95% |
05-15 | Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
1st Jan change | Capi. | |
---|---|---|
-83.95% | 2.17M | |
+15.73% | 121B | |
+20.14% | 114B | |
+17.23% | 23.61B | |
-18.66% | 20.43B | |
-15.57% | 16.55B | |
-13.87% | 16.45B | |
-44.35% | 15.59B | |
+71.02% | 15.19B | |
+2.06% | 13.54B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023